Regeneron's cemdisiran met phase 3 endpoints in myasthenia gravis with quarterly subcutaneous dosing, with detailed NIMBLE results published in The Lancet and a U.S. application filed. AstraZeneca's Ultomiris hit its primary endpoint in IgA nephropathy in the I CAN trial, positioning the complement C5 inhibitor for a fifth rare disease indication. Tortugas Neuroscience launched with $106 million to advance four phase 2-stage neurology assets from Eisai and Hansoh. Roche's Gazyva entered FDA review for systemic lupus erythematosus following positive phase 3 ALLEGORY data, with a decision expected by December 2026.
Top Stories
Regeneron's Cemdisiran Meets Phase 3 Endpoints in Myasthenia Gravis, Files for U.S. Approval
Regeneron announced that cemdisiran, an siRNA targeting complement factor C5 dosed subcutaneously at 600mg every 12 weeks, met the primary endpoint (2.3-point placebo-adjusted improvement in MG-ADL score at week 24) and all key secondary endpoints in the phase 3 NIMBLE trial for generalized myasthenia gravis in anti-AChR antibody-positive adults, according to a Regeneron press release and NeurologyLive. Cemdisiran achieved approximately 74% complement inhibition as monotherapy, with no meningococcal infections and no treatment discontinuations due to adverse events through 24 weeks. Detailed results were published in The Lancet and presented at the AAN Annual Meeting on April 21. The company has submitted a U.S. regulatory application, positioning cemdisiran as potentially the first siRNA approved for gMG — a market where quarterly dosing could prove a decisive differentiator.
AstraZeneca's Ultomiris Delivers Phase 3 Win in IgA Nephropathy, Eyes Fifth Rare Disease Indication
AstraZeneca reported that Ultomiris (ravulizumab) achieved a statistically significant and clinically meaningful reduction in proteinuria, measured by 24-hour urine protein creatinine ratio (UPCR), at week 34 in the I CAN phase 3 trial in adults with IgA nephropathy at risk of disease progression, with rapid proteinuria reduction observed as early as week 10, according to an AstraZeneca press release and Fierce Pharma. The I CAN trial randomized patients 1:1 to Ultomiris or placebo administered intravenously every eight weeks for 106 weeks; the long-term eGFR endpoint will be assessed at week 106. AstraZeneca plans to seek accelerated approval in key markets. The data position the complement C5 inhibitor for a potential fifth rare disease indication, adding to existing approvals in PNH, aHUS, gMG, and NMOSD.
FDA Accepts Pfizer-Astellas Priority Review for Padcev Combo in Muscle-Invasive Bladder Cancer
The FDA accepted for priority review a supplemental biologics license application for perioperative Padcev (enfortumab vedotin) combined with Keytruda (pembrolizumab) for muscle-invasive bladder cancer regardless of cisplatin eligibility, with a PDUFA target action date of August 17, 2026, according to Pharmaceutical Technology and a Pfizer press release. The sBLA is based on the phase 3 EV-304/KEYNOTE-B15 trial, which showed a 47% reduction in the risk of tumor recurrence, progression, or death and a 35% reduced risk of death versus neoadjuvant gemcitabine-cisplatin chemotherapy. Padcev plus Keytruda was approved in November 2025 for cisplatin-ineligible MIBC patients; this filing would expand access regardless of cisplatin eligibility.
Roche's Gazyva Enters FDA Review for Systemic Lupus Erythematosus
The FDA accepted Roche's supplemental biologics license application for Gazyva (obinutuzumab) for systemic lupus erythematosus, with a decision expected by December 2026, according to pharmaphorum and a Roche press release. The filing is based on the phase 3 ALLEGORY trial, published in the New England Journal of Medicine in March 2026, in which 76.7% of patients receiving Gazyva plus standard therapy achieved SRI-4 response at 52 weeks versus 53.5% for placebo (adjusted difference 23.1%, p<0.001), with superiority also demonstrated across all key secondary endpoints including BICLA response and glucocorticoid reduction to ≤7.5 mg/day. If approved, Gazyva would be the first anti-CD20 therapy to directly target B cells in SLE.
Tortugas Neuroscience Launches With $106M to Advance Asia-Licensed Neurology Pipeline
Two Sage Therapeutics veterans have launched Tortugas Neuroscience with $106 million in series A funding, backed by Cure Ventures, to advance four phase 2-stage neurology assets licensed from Eisai and Hansoh Pharma targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies, Fierce Biotech and a Tortugas press release reported. The neurology-focused startup emerges with a clinical-stage pipeline that bypasses early development risks while targeting unmet needs in CNS disorders. This represents a growing trend of Western biotechs in-licensing validated Asian assets and highlights continued investor appetite for neurology despite recent sector headwinds.
Ray Therapeutics Secures $125M Series B for Genetic Eye Therapy Development
Ray Therapeutics closed an upsized and oversubscribed $125 million series B financing led by Janus Henderson Investors to advance its optogenetic gene therapy platform for retinal degenerative diseases, according to Fierce Biotech and a Ray Therapeutics press release. The funding supports late-stage clinical development of lead program RTx-015 for retinitis pigmentosa — which recently received FDA RMAT designation — and clinical studies for RTx-021 in Stargardt disease and geographic atrophy. RTx-015 delivers a bioengineered light-sensitive protein via a single intravitreal injection to restore functional vision.
Asahi Kasei Completes Acquisition of German Biotech Aicuris
Japanese conglomerate Asahi Kasei completed its €780 million (~$921 million) acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company with three antiviral assets including Prevymis royalties, pritelivir (under FDA Priority Review with a PDUFA date in Q4 2026), and AIC468 (phase 1, for BK virus infections in transplant recipients), according to Pharmaceutical Technology and an Asahi Kasei press release. Aicuris will be integrated through Asahi Kasei's U.S. subsidiary Veloxis Pharmaceuticals, which specializes in transplant medicine, with combined revenue anticipated to reach $500 million by 2030. The deal, first announced in February 2026, signals continued cross-border M&A as Asian industrials build Western biopharma capabilities.
UnitedHealth Beats Q1 Expectations, Raises 2026 Profit Outlook
UnitedHealth Group reported Q1 adjusted earnings of $7.23 per share versus the $6.57 consensus estimate, on revenue of $111.72 billion, with the medical benefit ratio improving to 83.9% from 84.8% a year earlier (analysts expected 85.5%), and raised its full-year 2026 adjusted earnings outlook to more than $18.25 per share from a previous forecast above $17.75, according to STAT and CNBC. Shares jumped more than 8% in premarket trading. The nation's largest private insurer demonstrated its ability to manage high medical costs while growing revenue, which matters for biopharma as UnitedHealth's formulary decisions and reimbursement policies significantly influence market access for new therapeutics.
What to Watch
- Regeneron's cemdisiran approval timeline — With a U.S. application filed and NIMBLE data published in The Lancet, watch for FDA review acceptance and PDUFA dating; if approved, cemdisiran would be the first siRNA for gMG and could validate quarterly dosing as a competitive differentiator against existing complement inhibitors.
- Ultomiris accelerated approval pathway — AstraZeneca plans to seek accelerated approval based on week 34 proteinuria data from the I CAN trial; the confirmatory eGFR endpoint at week 106 and competitive positioning against atacicept and other IgAN therapies will be closely watched.
- Gazyva SLE decision by December 2026 — ALLEGORY's 23-point SRI-4 response difference (76.7% vs 53.5%) is the strongest anti-CD20 signal in lupus to date; approval would validate B-cell depletion in SLE and reshape the autoimmune treatment landscape.
- Padcev MIBC expansion by August 17 — The PDUFA date for cisplatin-eligible patient expansion could significantly broaden the perioperative market, with EV-304 data showing 47% reduction in recurrence risk versus chemotherapy.
Market Snapshot
- Complement therapeutics converge on autoimmune and renal indications: Regeneron's cemdisiran (siRNA, C5) in gMG and AstraZeneca's Ultomiris (mAb, C5) in IgAN both reported positive phase 3 data today, highlighting the broadening of complement-targeted approaches across rare autoimmune and renal diseases with distinct modalities competing for overlapping pharmacology.
- Optogenetic gene therapy gains institutional backing: Ray Therapeutics' upsized $125 million series B led by Janus Henderson, with RMAT-designated lead RTx-015 for retinitis pigmentosa, demonstrates that institutional investors are distinguishing optogenetic approaches from traditional gene replacement therapies after Luxturna's commercial challenges.
- Perioperative oncology combinations gain traction: The Padcev-Keytruda PDUFA date of August 17 for cisplatin-eligible MIBC patients, building on the November 2025 cisplatin-ineligible approval and EV-304 data showing 47% recurrence reduction, reflects broader industry momentum toward treating earlier-stage disease with ADC-IO combinations.